Portfolio Strategy and Decision Making for Biopharma Summit 2024
When:
Thursday, Nov 21, 2024 8:00a -
Friday, Nov 22, 2024 5:00p
Thursday, Nov 21, 2024 8:00a -
Friday, Nov 22, 2024 5:00p
Where:
Wyndham Boston Beacon Hill
5 Blossom Street
Boston, Massachusetts 02114
Admission:
$2599.00 - $3748.00
Hosted by:
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/2571452-0?pid=5248
The inaugural Portfolio Strategy and Decision Making for Biopharma Summit is a must-attend event for leaders in the pharma and biotech industries who are aiming to refine their portfolio strategies. This summit will offer unique insights into leveraging advanced data analytics and forecasting tools to make better decisions and navigate the volatile biopharma market.
Attendees will have the exclusive opportunity to network with over 60 industry leaders and learn from detailed case studies, best practices, and innovative approaches from both experienced big pharma and agile biotechs. The event will also focus on enhancing cross-functional collaboration and leveraging partnership opportunities.
This year, as the biopharma market faces unprecedented challenges and rapid changes, attending this summit is crucial for staying ahead. Join us to make informed decisions, mitigate risks, align stakeholders, and drive sustainable portfolio growth.
Analyse, Adapt, Respond and Implement to Mitigate Portfolio Risk!
URLs:
Tickets: https://go.evvnt.com/2571452-2?pid=5248
Brochure: https://go.evvnt.com/2571452-3?pid=5248
Prices:
Industry Pricing - Conference and Breakfast Briefing : USD 3048.00,
Industry Pricing - Conference Only: USD 2599.00,
Vendor Pricing - Conference and Breakfast Briefing: USD 3748.00,
Vendor Pricing - Conference Only: USD 3199.00
Speakers: Alaina Kupec, Executive Director of Portfolio Strategy and Analytics, Gilead, Amy House, Head of Portfolio Strategy, Beacon Therapeutics, Craig Ulmer, Senior Director of Global Program Management, Neuroscience,Takeda, Darshan Shah, Executive Director, Incyte, David Yee, Head of Portfolio Systems, Portfolio Strategy and Analytics, Novartis, Douglas Macdonald, Ph.D. Director of Research Operations and Scientific Alliances, CHDI Management Inc., Giuseppe Ciavarro, Head of Enterprise Portfolio Governance, Novartis, Jonathan Dabora, Founder and Principal, Concord Life Sciences LLC, Phil Gregory, Director of Alliance Management, KSQ Therapeutics, Raya Mareva, Director of RLT Strategy and Early Portfolio, Novartis, Richard Van, Healthcare Innovation and Strategy Lead, US Immunology, UCB, Ritu Kamal, Director of Portfolio Strategy, Illumina, Samir Vattomppadam, Senior Vice President of Portfolio Strategy and Program Management, Vor Bio, Sarah Hudson, Senior Director of Portfolio Strategy and Program Management, Avidity Biosciences, Satinder Rawat, Ph.D. MBA Corporate Strategy and Business Development Advisor, Independent Consultant, Steve Seredick, Director of Portfolio Strategy, Zymeworks, Susie Bourne, Director of Clinical Study Planning and Resource Forecasting, Amgen, Tarun Walia, Senior Director of Data Science Evaluation and Integration Strategy, Novo Nordisk, Wendy Cheung, Pharm.D. Senior Vice President of Portfolio Strategy and Program Management, AbbVie
